Core Viewpoint - The announcement details a technical service contract signed between Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. and WuXi AppTec Co., Ltd. to enhance drug development capabilities and reduce clinical trial time and costs, which will not adversely affect the company's financial status or operational results [16]. Group 1: Contract Details - The total amount of the contract is 10,800,000.00 yuan, including a 6% tax, with payments to be made in installments as per the contract terms [3]. - The contract is valid for three years, starting from the date of signing, and will automatically extend until the completion of the project if it is not finished by the expiration date [9]. - All technical service results generated under this contract will belong to the company, which retains the rights to apply for patents [4]. Group 2: Parties Involved - Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. is a wholly-owned subsidiary of the company, holding 97.9545% of its shares, with a registered capital of 440 million yuan [10][11]. - WuXi AppTec Co., Ltd. has a registered capital of 1.05 billion yuan and specializes in drug development services [13]. Group 3: Financial Impact - The contract is expected to enhance the company's drug research and development capabilities, potentially leading to more efficient clinical trials and cost savings [16]. - The financial data of Sichuan Luzhou Buchang indicates total assets of 234,047.98 million yuan and a net asset of 21,929.81 million yuan as of June 30, 2025 [13].